Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) have rallied back from the patent cliff as well as any companies in big pharma, and both these standout firms have looked toward the future in igniting investor optimism. But one drug captured all the hype around these two companies before its approval in the final days of 2012: blood thinner Eliquis.

Yet Eliquis hasn't met those high hopes in its first full year on the market. The drug's managed tepid sales at best, and Wall Street analysts have toned down 2014's expectations for Eliquis, a drug that once garnered peak sales estimates of up to $4 billion annually. Bristol and Pfizer aren't giving up on this promising yet sluggish therapy, but will Eliquis turn things around for investors cautious about the drug's future?

Eliquis's most recent approval might be the first spark of hope for this drug after a slow market debut. Find out how this promising drug can mount a comeback in the video below, as Motley Fool contributor Dan Carroll takes you through the latest on Eliquis -- and whether or not Pfizer, Bristol, and investors can rely on this ballyhooed medication to emerge as a blockbuster powerhouse in the future.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.